BioCentury
ARTICLE | Clinical News

Ixazomib: Additional Phase III data

November 23, 2015 8:00 AM UTC

Additional data from the double-blind, international Phase III TOURMALINE-MM1 trial in 722 patients with relapsed or refractory MM showed that 4 mg oral ixazomib on days 1, 8 and 15 of a 28-day cycle ...